Fluxum

12/25/2001 - "Clinical data of 297 patients with acute pulmonary embolism were registered in 21 hospitals in China that participated in the "multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/ or anticoagulation with low molecular weight heparin (Fluxum) in patients with acute pulmonary embolism" from August 1997 to July 1999. "
07/01/1988 - "A multicentric study was carried out involving six italian departments of general surgery to assess the efficacy of a low molecular weight (LMW) heparin called Fluxum compared to standard calcium heparin in low doses for prevention of postoperative thromboembolic complications (deep vein thrombosis and pulmonary embolism). "

12/01/1993 - "We conclude that Fluxum (LMWH) for the efficacy and convenience given by a single daily dose, could represent an alternative choice in the prevention of deep venous thrombosis in cardiac surgery."
12/01/1993 - "Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery."
07/01/1988 - "A multicentric study was carried out involving six italian departments of general surgery to assess the efficacy of a low molecular weight (LMW) heparin called Fluxum compared to standard calcium heparin in low doses for prevention of postoperative thromboembolic complications (deep vein thrombosis and pulmonary embolism). "
01/01/2008 - "Parnaparin (Fluxum) is a low molecular weight heparin (LMWH) that is effective and generally well tolerated in the prevention of venous thrombosis, and in the treatment of chronic venous disease and venous and arterial thrombosis. "

02/01/2014 - "Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum)."
01/01/2020 - "[The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis]."
01/01/2020 - "A comparative assessment of the effectiveness and clinical safety of thrombosis prevention in the treatment of lower limb bone fractures using low-molecular weight heparins: parnaparin sodium (Fluxum) and enoxaparin sodium. "
01/01/2020 - "The goal is to compare the effectiveness and clinical safety of using parnaparin sodium (Fluxum) and enoxaparin sodium as the prevention of thrombosis in the treatment of lower limb bone fractures. "
02/01/2014 - "To evaluate risk factors for recurrent events in patients enrolled in the SteFlux (Superficial Thromboembolism Fluxum) clinical trial which compared different doses and duration of low molecular weight heparin (parnaparin) for superficial vein thrombosis (SVT). "

02/01/2014 - "Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum)."
02/01/2014 - "To evaluate risk factors for recurrent events in patients enrolled in the SteFlux (Superficial Thromboembolism Fluxum) clinical trial which compared different doses and duration of low molecular weight heparin (parnaparin) for superficial vein thrombosis (SVT). "
06/01/2012 - "A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)."

01/01/2020 - "A comparative assessment of the effectiveness and clinical safety of thrombosis prevention in the treatment of lower limb bone fractures using low-molecular weight heparins: parnaparin sodium (Fluxum) and enoxaparin sodium. "
01/01/2020 - "The goal is to compare the effectiveness and clinical safety of using parnaparin sodium (Fluxum) and enoxaparin sodium as the prevention of thrombosis in the treatment of lower limb bone fractures. "